In this section
Eu2P European master’s degree
European master's in Pharmacovigilance and Pharmacoepidemiology
Objectives and added value
The Eu2P master’s degree is a joint European programme (120 ECTS credits) in the field of drug monitoring and pharmaco-epidemiology offered by 6 European universities all leaders in the field (cf. the list of partners).
Furthermore, this master’s degree is recognised by 15 pharmaceutical firms acting as partners in the diploma, the European Drug Agency and the French Agency for the Safety of Health Products.
The Eu2P master’s degree was developed under the 7th Framework Programme as part of a joint technological initiative project in the field of innovative drugs, coordinated by UBxS and Hoffmann-La Roche AG.
This project aims more widely at building an integrated European course both for students (with a master’s degree or PhD) and for those working in industry and regulatory organisations within the framework of continuing education. A joint Eu2P doctorate programme in the field of drug monitoring is currently being designed and will be launched shortly.
The Eu2P master’s degree trains health professionals in the practice and/or research of pharmaco-epidemiology and drug monitoring for application in medicine, pharmacy and public health in the various regulatory agencies and in the pharmaceutical industry.
Duration and teaching language
A 2-year master’s degree (12 ECTS), with courses given in English.
Level of access
Holders of a bachelor’s degree in health or life sciences.
Access possible in M2 upon examination of the student’s dossier.
For further information, consult the Web site of the programme.
The first year of the Eu2P master’s degree offers a joint programme of modules provided by the partner universities through distance learning on Internet. Specialisation is organised in the second year according to 6 possible courses. Compulsory research placements are organised in the 2nd and 4th semesters.
A joint diploma entitled ‘Master in Pharmacovigilance and Pharmacoepidemiology’ will be awarded to students having successfully completed their courses.
Cost of the programme
7,000€ / year for students and 12,000€ / year for professionals.
- 7 universities: UBxS; Erasmus Universitair Medisch Centrum Rotterdam, Universiteit Utrecht in the Netherlands; University of Hertfordshire in the UK; Universita di Verona in Italy; Fundacio Institut Catala de Farmacologia in Spain; Karolinska Institute in Sweden.
- 2 health regulatory agencies (European and French agencies): European Medicines Agency and the French Agency for the Safety of Health Products.
- 15 European pharmaceutical firms (F. Hoffmann-La Roche AG, Amgen NV, AstraZeneca AB, Bayer Schering Pharma AG, BoehringerIngelheim, International GmbH, Eli Lilly and Company Limited, GlaxoSmithKline Research and Development Ltd., H. Lundbeck A/S, Janssen Pharmaceutica NV, LaboratoriosAlmirall SA, Novartis Pharma AG, Novo Nordisk A/S, Orion Corporation, Sanofi-aventis Research and Development, UCB Pharma SA)